Search results
NGM Bio Plunges As Experimental Drug Fails To Meet Primary Goal In Age-Related Vision Loss Disorder
Benzinga via Yahoo Finance· 2 years agoNGM Biopharmaceuticals Inc (NASDAQ: NGM) announced topline efficacy and safety results from its...
NGM Bio To Highlight Updated Preliminary Findings From Advanced Solid Tumors Trial
Benzinga via Yahoo Finance· 2 years agoNGM Biopharmaceuticals Inc's (NASDAQ: NGM) updated preliminary findings from its Phase 1a study of...
Clinical Setbacks Prompt NGM Bio Lay Off One Third Of Its Staff, Founder Leaves
Benzinga via Yahoo Finance· 1 year agoNGM Biopharmaceuticals Inc (NASDAQ: NGM) announced will be reducing its workforce by 75 staffers, or...
NGM Bio Presents Preliminary Data From NGM120 Combo Trial In Pancreatic Cancer
Benzinga via Yahoo Finance· 2 years agoNGM Biopharmaceuticals Inc (NASDAQ: NGM) announced updated preliminary findings from its Phase 1b...
NGM Biopharmaceuticals (NGM) Reports Q2 Loss, Misses Revenue Estimates
Zacks via Yahoo Finance· 10 months agoNGM Biopharmaceuticals (NGM) delivered earnings and revenue surprises of 0% and 42.30%,...
Bluebird Bio (BLUE) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
Zacks via Yahoo Finance· 2 years agoBluebird (BLUE) doesn't possess the right combination of the two key ingredients for a likely...
Merck to buy eye drug developer for $1.3B
BioPharma Dive via Yahoo Finance· 1 week agoAn acquisition of EyeBio will hand Merck a treatment for diabetic macular edema and age-related macular degeneration that’s ready for pivotal testing.